61494-55-1

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-3-pyridineacetic acid is used as a chemical intermediate for the synthesis of RORγ agonists, which are a class of compounds that target the Retinoid-Related Orphan Receptor Gamma. These agonists have potential therapeutic applications in the treatment of cancer, as they can modulate the activity of the RORγ receptor and influence various cellular processes related to cancer progression and immune response.

Physical Form

Solid

InChI:InChI=1/C7H6ClNO2/c8-7-5(4-6(10)11)2-1-3-9-7/h1-3H,4H2,(H,10,11)

Upstream product

• 101012-32-2 2-(2-chloropyridin-3-yl)acetonitrile 
• 40134-18-7 methyl 2-chloropyridine-3-carboxylate 
• 166770-75-8 (2-chloropyridin-3-yl)methyl methanesulfonate 
• 286836-24-6 (7-bromobenzofuran-5-yl)methanol 
• 42330-59-6 (2-chloropyrid-3-yl)methanol 
• 89581-84-0 2-chloro-3-(chloromethyl)pyridine 
• 773837-37-9 sodium cyanide 
• 6959-48-4 3-chloromethylpyridinium chloride 
• 6635-88-7 3-(cyanomethyl)pyridine 1-oxide 
• 6443-85-2 3-pyridinylacetonitrile 

Downstream Products

• 127555-83-3 1-(2,4-Difluoro-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one 
• 127555-70-8 1-(4-Chlorophenyl)-1,3-dihydro-2H-pyrrolo[2,3-b]-pyridin-2-one 
• 127555-16-2 1-(4-Methoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one 
• 127555-84-4 1-(3,5-Dichloro-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one 
• 956434-27-8 N-benzyl-2-(2-chloropyridin-3-yl)-N-(2-hydroxyethyl)acetamide 
• 6419-36-9 3-pyridineacetic acid hydrochloride 
• 1202067-21-7 3-[(2,2-dimethyltetrahydro-5H-[1,3]dioxolo[4,5-c]pyrrol-5-yl)carbonyl]-N-(2-fluoro-4-iodophenyl)thieno[2,3-b]pyridin-2-amine 
• 1202067-35-3 (cis-3,4-dihydroxypyrrolidin-1-yl)-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]methanone 
• 1202066-93-0 5-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridine-3-carbonyl]-3-methyl-hexahydropyrrolo[3,4-d]oxazol-2-one 
• 1202066-95-2 (3aR,6aS)-5-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridine-3-carbonyl]-tetrahydro[1,3]dioxolo[4,5-c]pyrrol-2-one 
• 1202067-94-4 [(3S,4S)-3-amino-4-hydroxypyrrolidin-1-yl]-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]-methanone 
• 1202067-39-7 [(3R,4S)-3-amino-4-hydroxypyrrolidin-1-yl]-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]-methanone 
• 1202067-89-7 [(3S,4R)-3-amino-4-hydroxypyrrolidin-1-yl]-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]-methanone 
• 1202068-00-5 [2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]-[(3S,4S)-3-hydroxy-4-(methylamino)pyrrolidin-1-yl]-methanone 

Relevant academic research and scientific papers

TOPICAL FORMULATIONS

Provided herein are gelled topical formulations for the treatment of skin diseases comprising: a) a MEK inhibitor; b) one or more organic solvents in an amount of about 70% to about 99% by weight; and c) a gelling agent; wherein the one or more organic solvents are selected from the group consisting of C2-6 alcohol, a C2-6 alkylene glycol, a di-(C2-6 alkylene) glycol, a polyethylene glycol, C1-3 alkyl-(OCH2CH2)1-5-OH, DMSO, ethyl acetate, acetone, N-methyl pyrrolidone, benzyl alcohol, glycerin, and an oil; the gelling agent is hydroxypropyl cellulose having a molecular weight ranging from about 40,000 Dato about 2,500,000 Da; and wherein the gelled topical formulation has a viscosity of from 1 to 25,000 cps; and DMSO, when present, is combined with at least one other of said organic solvents such that DMSO is present in an amount of less than 50% by weight.

ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS

Provided herein are compounds and pharmaceutical compositions thereof for treating a birthmark in a subject in need thereof, wherein the compound is according to any one of formula (1), (II), (III), (IV), and (V). wherein X1, X2, X3, R1, R2, R2a, R13, R13a, R23, R23a, R23b, R33, R33a, R33b, R43, R43a, R51, R53, R53a, R53b, bond "a", and subscript n are described herein.

ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS

Provided herein are compounds and pharmaceutical compositions thereof for treating a skin cancer in a subject in need thereof, wherein the compound is according to any one of formula (I), (II), (III), (IV), and (V): wherein X1, X2, X3, R1, R2, R2a, R13, Rl3a, R23, R23a, R23b, R33, R33a, R33b, R43, R43a, R51, R53, R53a, R53b, bond "a", and subscript n are described herein.

SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS

Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

Preparation method of 3-pyridylacetic acid hydrochloride

The invention discloses a preparation method of 3-pyridylacetic acid hydrochloride and belongs to the field of chemistry. A 3-pyridylacetic acid hydrochloride product is prepared from 3-methylpyridine chlorination side product 2-chloro-3-methylpyridine as a raw material through cyanidation, alkaline hydrolysis, hydrogenation reduction and salification. The 3-pyridylacetic acid hydrochloride product has purity of 98.5% or more.

FAK AND FLT3 INHIBITORS

The use of a compound of the formula (I): (Formula (I)) in the preparation of a medicament for treating Acute Myeloid Leukemia or a disease ameliorated by the inhibition of Flt3, or Flt3 and FAK.

FAK INHIBITORS

A compound of the formula (I): where R1 or R2 is a cycle amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.

THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS

A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2- position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment, of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.

THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS

The invention provides a series of thieno[2,3-b]pyridine derivatives wherein Y represents a linkage of formula C(O) or S(O)2; R1 represents hydrogen, halogen, cyano, nitro, C|-6 alkyl, trifluoromethyl, Ci.6 alkoxy, trifluoromethoxy,

THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS

A series of thieno[2,3-6]pyridine derivatives, attached at the 2-position to a substituted anilino moiety, which are substituted in the 3-position by a carbonyl group linked to a pyrrolidin-1-yl ring which in turn forms part of a heteroatom-containing fus